Tropical Medicine
Liver function tests (LFT)
Tropical Medicine
Well covered in the main question banks · 38 main-bank entries · 114 linked PDF entries · 0 generated drills
Curriculum reference · Official College Textbook – Digestive Disorders – Part 2, pp. 91–98. Lesson adapted from Internal Medicine and Tropical Medicine.
Topic map
- Hepatocyte injuryALT and AST
- CholestasisALP, GGT and direct bilirubin
- Synthesisalbumin and PT/INR
- Resolve causeprobabilities, imaging, fibrosis tests and selected biopsy
Scroll the diagram to see all labels.
Chemistry, bilirubin and interpretation
- Initial assessment
- Establish enzyme pattern, bilirubin fractions and synthetic function
- Confirmation or next test
- GGT supports hepatic ALP; ultrasound, serology and further staging follow the pattern
ALT is more liver-specific than AST [IM Mid Q1/Q5 · IM Dept LFT Q4]. AST is also present in muscle and myocardium, so muscle injury or myocardial infarction [IM Mid Q4] can elevate it. Acute viral hepatitis often shows ALT greater than AST [IM Mid Q6 · IM Dept LFT Q2], whereas cirrhosis can reverse the ratio. AST above ALT [IM Mid Q7–10/Q30] can occur with alcohol-associated injury and advanced fibrosis, but a ratio alone cannot identify the cause. Metabolic steatohepatitis often has ALT predominance early and enzymes can be normal in advanced disease. Very high aminotransferases raise consideration of ischemia, acetaminophen toxicity or acute viral/drug injury.
ALP [IM Mid Q11–12] originates in liver, bone, placenta and intestine. A concomitant GGT rise [IM Dept LFT Q5] supports a hepatobiliary source. Infiltrative metastases and PBC can cause markedly high ALP and values above 1000 IU/L appear in the course bank; they are nonspecific. Isolated GGT can reflect alcohol or drug enzyme induction and does not diagnose either. With suspected drug injury, R = (ALT/ULN) ÷ (ALP/ULN), with ≥5 hepatocellular, ≤2 cholestatic and between mixed.
Heme yields water-insoluble unconjugated bilirubin [IM Dept Jaundice Q2], carried by albumin and absent as urine bilirubin. UGT1A1 conjugates it for bile excretion. Gut bacteria produce urobilinogen, some renally excreted, while stool pigments give brown color. Hemolysis raises indirect bilirubin and urinary urobilinogen [IM Dept pp. 9, 27]. Hepatocellular jaundice can be mixed. Obstruction increases direct bilirubin and causes bilirubinuria, dark urine and reduced bowel/urine urobilinogen [IM Dept pp. 9, 27–28]. Complete obstruction can give acholic stool and high ALP/GGT. Jaundice visibility is not a fixed threshold; separate department stems use roughly 2–3 mg/dL. Yellow skin with spared sclerae suggests carotenoderma.
Synthesis, specific etiologic tests and fibrosis
Albumin measures synthetic function [IM Mid Q2–3], changes slowly and can be low in inflammation, malnutrition, renal or enteric losses. PT/INR responds faster [IM Dept LFT Q1] because clotting factors have short half-lives. Exclude vitamin K deficiency or medication effects. A rising INR with encephalopathy, confusion, asterixis or stupor in acute injury is urgent. INR is not a standalone bleeding-risk gauge in cirrhosis. Thrombocytopenia can signal portal hypertension or other causes.
PBC often has positive AMA and raised IgM [IM Mid Q15/Q17/Q31–32], while AIH often has high IgG [IM Mid Q16]. Choose testing based on pattern: viral serology, ANA/SMA and IgG, AMA, iron studies, Wilson evaluation or other targeted tests. AFP [IM Mid Q14/Q21] is an adjunct in HCC surveillance/assessment and cannot establish HCC alone. In pregnancy maternal or amniotic AFP can rise with open neural tube defects. Imaging characteristics, clinical context and selected biopsy determine focal-lesion diagnosis.
APRI, FibroTest and ELF [IM Mid Q18–20] estimate fibrosis with distinct inputs. APRI combines AST normalized to ULN and platelets. FIB-4 uses age, AST, ALT and platelets. ELF uses extracellular matrix turnover markers. Elastography estimates stiffness, with inflammation/congestion as confounders. Choose thresholds by disease and patient context.
Imaging and biopsy
Ultrasound first [IM Mid Q23] surveys liver and bile ducts; Doppler evaluates flow. A palpable nontender gallbladder with jaundice (Courvoisier sign) raises suspicion of malignant distal obstruction. MRCP shows ducts noninvasively, and ERCP allows targeted therapy. Contrast MRI for focal lesion characterization [IM Mid Q22/Q24] is the course choice, with multiphase CT also important in context. Biopsy can establish histology when it changes management. The course lists INR >1.5, platelets below 50 × 10⁹/L, ascites, inability to cooperate and extrahepatic obstruction [IM Mid Q25–29] as usual percutaneous concerns. Actual thresholds and route depend on biopsy indication, local practice and specialist assessment; consider transjugular access when appropriate.
Exam traps
ALT/AST indicate injury, while albumin and PT/INR describe synthesis. ALP alone can come from bone. GGT helps localize ALP and is not a general screening test for alcohol use. High AFP can support a diagnosis in context but does not replace imaging.
Diagnostic and management pathways
- Confirm abnormality and check acuity → review medicines, alcohol, metabolic and infectious risks
- Hepatocellular → directed serology and exposure evaluation
- Cholestatic → confirm hepatic ALP with GGT → ultrasound, then duct studies when indicated
- Assess INR/albumin, fibrosis and focal lesions → selective biopsy if results will change care
Compare at a glance
| Pattern | Key labs | Typical next step |
|---|---|---|
| Hepatocellular | ALT/AST disproportionate | Review viral, drug, ischemic, metabolic and autoimmune causes |
| Cholestatic | ALP and GGT disproportionate; may have direct bilirubin | Ultrasound, duct studies or AMA by context |
| Unconjugated jaundice | Indirect fraction, no bilirubinuria | Hemolysis or conjugation disorders |
| Synthetic dysfunction | High INR or low albumin | Review acuity, confounders and liver severity |
Supplementary clarification – not directly stated in the uploaded materials. Clinical references · ACG evaluation of abnormal liver chemistries
Exam words
- ALT is more liver-specific than AST [IM Mid Q1/Q5 · IM Dept LFT Q4]
- myocardial infarction [IM Mid Q4]
- ALT greater than AST [IM Mid Q6 · IM Dept LFT Q2]
- AST above ALT [IM Mid Q7–10/Q30]
- ALP [IM Mid Q11–12]
- GGT rise [IM Dept LFT Q5]
- unconjugated bilirubin [IM Dept Jaundice Q2]
- Hemolysis raises indirect bilirubin and urinary urobilinogen [IM Dept pp. 9, 27]
- Obstruction increases direct bilirubin and causes bilirubinuria, dark urine and reduced bowel/urine urobilinogen [IM Dept pp. 9, 27–28]
- Albumin measures synthetic function [IM Mid Q2–3]
- PT/INR responds faster [IM Dept LFT Q1]
- PBC often has positive AMA and raised IgM [IM Mid Q15/Q17/Q31–32]
- AIH often has high IgG [IM Mid Q16]
- AFP [IM Mid Q14/Q21]
- APRI, FibroTest and ELF [IM Mid Q18–20]
- Ultrasound first [IM Mid Q23]
- Contrast MRI for focal lesion characterization [IM Mid Q22/Q24]
- INR >1.5, platelets below 50 × 10⁹/L, ascites, inability to cooperate and extrahepatic obstruction [IM Mid Q25–29]
Practice questions
Rapid revision sheet
Sixty-second recall. Say the definition, the key clue and the next clinical step out loud before checking the list.
- ALT is more liver-specific than AST [IM Mid Q1/Q5 · IM Dept LFT Q4]
- myocardial infarction [IM Mid Q4]
- ALT greater than AST [IM Mid Q6 · IM Dept LFT Q2]
- AST above ALT [IM Mid Q7–10/Q30]
- ALP [IM Mid Q11–12]
- GGT rise [IM Dept LFT Q5]
Official College Textbook – Digestive Disorders – Part 2, pp. 91–98
Active recall
How does a hepatocellular biochemical pattern differ from a cholestatic pattern?
Disproportionate ALT/AST elevation favors hepatocellular injury. Disproportionate alkaline phosphatase elevation favors cholestasis, and GGT can support a hepatic origin.
Official College Textbook – Digestive Disorders – Part 2, pp. 91–98
Recall the diagnostic and management pathway from memory.
Start with the presenting clue, name the first assessment, then distinguish confirmation, immediate management and follow-up.
- Confirm abnormality and check acuity → review medicines, alcohol, metabolic and infectious risks
- Hepatocellular → directed serology and exposure evaluation
- Cholestatic → confirm hepatic ALP with GGT → ultrasound, then duct studies when indicated
- Assess INR/albumin, fibrosis and focal lesions → selective biopsy if results will change care